Cargando…

Plasma Clusterin Concentrations May Predict Resistance to Intravenous Immunoglobulin in Patients with Kawasaki Disease

Kawasaki disease (KD) is an acute febrile vasculitic syndrome of early childhood often complicated by coronary artery lesion that drastically reduces the quality of life. The study aimed to identify a reliable marker for predicting nonresponsiveness to the first course of intravenous immunoglobulin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ou-Yang, Mei-Chen, Kuo, Ho-Chang, Lin, I-Chun, Sheen, Jiunn-Ming, Huang, Fu-Chen, Chen, Chih-Cheng, Huang, Ying-Hsien, Lin, Ying-Jui, Yu, Hong-Ren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3727184/ https://www.ncbi.nlm.nih.gov/pubmed/23956692 http://dx.doi.org/10.1155/2013/382523

Ejemplares similares

Sonographic Gallbladder Abnormality Is Associated with Intravenous Immunoglobulin Resistance in Kawasaki Disease
por: Chen, Chih-Jen, et al.
Publicado: (2012)

Comparison of the Laboratory Data Between Kawasaki Disease and Enterovirus After Intravenous Immunoglobulin Treatment
por: Lin, Li-Yan, et al.
Publicado: (2012)

C-Reactive Protein to Albumin Ratio for Predicting Coronary Artery Lesions and Intravenous Immunoglobulin Resistance in Kawasaki Disease
por: Tsai, Chih-Min, et al.
Publicado: (2020)

Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial
por: Kuo, Ho-Chang, et al.
Publicado: (2018)

Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia
por: Yu, Hun-Ju, et al.
Publicado: (2021)

Randomized trial of different initial intravenous immunoglobulin regimens in Kawasaki disease
por: He, Lan, et al.
Publicado: (2021)

Plasma Prostaglandin E(2) Levels Correlated with the Prevention of Intravenous Immunoglobulin Resistance and Coronary Artery Lesions Formation via CD40L in Kawasaki Disease
por: Kuo, Ho-Chang, et al.
Publicado: (2016)

Predictors for Intravenous Immunoglobulin Resistance in Patients with Kawasaki Disease
por: Li, Wei, et al.
Publicado: (2022)

Comparative effectiveness of two intravenous immunoglobulin products in children with Kawasaki disease, a nationwide cohort study
por: Kuo, Ni-Chun, et al.
Publicado: (2023)

Intravenous immunoglobulin for the treatment of Kawasaki disease
por: Broderick, Cathryn, et al.
Publicado: (2023)

Hepcidin-Induced Iron Deficiency Is Related to Transient Anemia and Hypoferremia in Kawasaki Disease Patients
por: Huang, Ying-Hsien, et al.
Publicado: (2016)

Prediction of repeated intravenous immunoglobulin resistance in children with Kawasaki disease
por: Lu, Yaheng, et al.
Publicado: (2021)

Evaluation of Formosa score and diagnostic sensitivity and specificity of four Asian risk scores for predicting intravenous immunoglobulin resistance in Kawasaki disease: a bivariate meta-analysis
por: Chiang, Wan-Ni, et al.
Publicado: (2023)

Comparative Effectiveness of Intravenous Immunoglobulin for Children with Kawasaki Disease: A Nationwide Cohort Study
por: Lin, Ming-Chih, et al.
Publicado: (2013)

Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease
por: Xie, Tian, et al.
Publicado: (2017)

Risk Factors and Predictive Models for Intravenous Immunoglobulin Resistance in Children with Recurrent Kawasaki Disease
por: Chen, Xi, et al.
Publicado: (2022)

Treatment of Kawasaki Disease: A Network Meta-Analysis of Four Dosage Regimens of Aspirin Combined With Recommended Intravenous Immunoglobulin
por: Huang, Ying-Hua, et al.
Publicado: (2021)

Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease
por: Park, Hyo Min, et al.
Publicado: (2013)

Predictors and management of intravenous immunoglobulin-resistant Kawasaki disease
por: Song, Min Seob
Publicado: (2019)

Kawasaki disease: Aetiopathogenesis and therapeutic utility of intravenous immunoglobulin
por: Galeotti, Caroline, et al.
Publicado: (2010)

Intravenous Immunoglobulin in Kawasaki Disease—Evolution and Pathogenic Mechanisms
por: Nadig, Pallavi L., et al.
Publicado: (2023)

Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease
por: Ma, Yongmei, et al.
Publicado: (2022)

Immunoglobulin profiling identifies unique signatures in patients with Kawasaki disease during intravenous immunoglobulin treatment
por: Ko, Tai-Ming, et al.
Publicado: (2018)

The Efficacy and Safety of High-Dose Intravenous Immunoglobulin in the Treatment of Kawasaki Disease: How Can We Predict Resistance to Intravenous Immunoglobulin Treatment of Kawasaki Disease?
por: Han, Ji Whan
Publicado: (2017)

Nomogram to predict risk of resistance to intravenous immunoglobulin in children hospitalized with Kawasaki disease in Eastern China
por: Huang, Hongbiao, et al.
Publicado: (2022)

Neutrophil-to-Lymphocyte Ratio Predicts Intravenous Immunoglobulin-Resistance in Infants Under 12-Months Old With Kawasaki Disease
por: Chen, Yongbing, et al.
Publicado: (2019)

Prediction of Resistance to Standard Intravenous Immunoglobulin Therapy in Kawasaki Disease
por: Lee, Sang Min, et al.
Publicado: (2014)

Hemolysis From Intravenous Immunoglobulin in Obese Patients With Kawasaki Disease
por: Van Anh, Khanh-Van Y., et al.
Publicado: (2020)

Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases
por: Li, Xuan, et al.
Publicado: (2018)

Retracted: Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease
por: Healthcare Engineering, Journal of
Publicado: (2023)

A New Scoring System for Prediction of Intravenous Immunoglobulin Resistance of Kawasaki Disease in Infants Under 1-Year Old
por: Wu, Shu, et al.
Publicado: (2019)

FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease
por: Kuo, Ho-Chang, et al.
Publicado: (2015)

Serum proteins may facilitate the identification of Kawasaki disease and promote in vitro neutrophil infiltration
por: Li, Sung-Chou, et al.
Publicado: (2020)

Identifying Downregulation of Autophagy Markers in Kawasaki Disease
por: Huang, Fu-Chen, et al.
Publicado: (2020)

Factors Predicting Resistance to Intravenous Immunoglobulin and Coronary Complications in Kawasaki Disease: IVIG Resistance in Kawasaki Disease
por: Han, Ji Whan
Publicado: (2017)

A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?
por: Li, Wei, et al.
Publicado: (2021)

Significantly Lower Immunoglobulin M Levels 6 Months After Disease Onset in Patients With Kawasaki Disease With Coronary Artery Lesions
por: Chang, Ling‐Sai, et al.
Publicado: (2021)

Risk Factors for Failure of Initial Intravenous Immunoglobulin Treatment in Kawasaki Disease
por: Cha, Sungho, et al.
Publicado: (2008)

Low-dose Methotrexate Therapy for Intravenous Immunoglobulin-resistant Kawasaki Disease
por: Lee, Taek Jin, et al.
Publicado: (2008)

High-Concentration Intravenous Immunoglobulin May Influence the Course of Fever and Rate of Reported Treatment Resistance in Children With Kawasaki Disease: A Single-Center Retrospective Analysis
por: Han, Seung Beom, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8qevvfbtof2bufrggg1dl3buii